Parameter | Treatment group | |||
---|---|---|---|---|
Placebo n = 133 | 300IR (2 M) n = 117 | 300IR (4 M) n = 127 | Total N = 377 | |
Gender, n (%) | ||||
Male | 79 (59.4) | 71 (60.7) | 81 (63.8) | 231 (61.3) |
Female | 54 (40.6) | 46 (39.3) | 46 (36.2) | 146 (38.7) |
Age, years | ||||
n | 133 | 117 | 127 | 377 |
Mean (SD) | 30.1 (8.7) | 30.9 (7.8) | 30.5 (8.5) | 30.5 (8.3) |
Range | 18–49 | 18–51 | 18–49 | 18–51 |
Body mass index, kg/m 2 | ||||
n | 132 | 117 | 127 | 376 |
Mean (SD) | 23.9 (4.3) | 24.3 (3.9) | 24.2 (3.7) | 24.1 (4.0) |
Range | 15.6–42.4 | 17.3–35.1 | 17.2–35.1 | 15.6–42.4 |
Duration of ARC, years | ||||
n | 133 | 117 | 127 | 377 |
Mean (SD) | 12.5 (9.0) | 12.9 (8.8) | 13.0 (9.2) | 12.8 (9.0) |
Range | 1.6–44.0 | 1.5–39.0 | 1.5–42.1 | 1.5–44.0 |
RRTSS | ||||
n | 133 | 117 | 127 | 377 |
Mean (SD) | 14.0 (1.7) | 13.9 (1.8) | 14.2 (1.7) | 14.1 (1.7) |
Range | 12–18 | 12–18 | 12–18 | 12–18 |
Asthma status, n (%) | ||||
Yes | 19 (14.3) | 13 (11.1) | 16 (12.6) | 48 (12.7) |
No | 114 (85.7) | 104 (88.9) | 111 (87.4) | 329 (87.3) |
Sensitization status, n (%) | ||||
Monosensitized | 53 (39.8) | 47 (40.2) | 53 (41.7) | 153 (40.6) |
Polysensitized | 80 (60.2) | 70 (59.8) | 74 (58.3) | 224 (59.4) |